Femtouch: Non-Surgical Laser Vaginal Rejuvenation
FemTouch was developed by Lumenis®, the pioneer of laser medicine, in collaboration with leading medical specialists. FemTouch is FDA cleared and clinically validated to deliver optimal results for improved vaginal health.
The Lumenis® FemTouch is an effective and comfortable non-surgical, out-patient, in-office, non-hormonal therapy for improved vaginal health. Optimal outcomes just after 2-4 sessions taking a few minutes each. No anesthesia or special post procedure care is required.
FemTouch is state of the art CO2 laser technology that addresses vaginal health related conditions by promoting the remodeling of vaginal mucous layer. A better term for this process may be “Revitalization.” The Fractional CO2 laser is applied along the vaginal wall which results in very gentle controlled ablation and coagulation of the vaginal lining.
With age and after childbirth, women start noticing symptoms related to their vaginal health that affect their lifestyle on different levels.
Vaginal atrophy or dryness is a common symptom among post-menopausal women, while nearly 80% of the women are likely to suffer from it. Vaginal and urogenital atrophy are usually associated with hypoestrogenism – the decreased estrogenization of the vulvovaginal tissue. Decreased estrogenization usually results in a decrease in secretions which increases the risk of urinary tract infection (UTI). Other related symptoms can include vaginal irritation, burning unrelated to urination, soreness after intercourse and post-coital bleeding.
Stress urinary incontinence (SUI) is another symptom appearing also in a younger demographic, in some cases already among women 20-45 years old. 50% of post-menopausal women are likely to suffer from SUI.
Urinary symptoms can include urine frequency, urgency, and urge incontinence.
Women who have undergone childbirth will often notice symptoms of vaginal laxity which can impact their satisfaction with sexual intercourse.
Treatment of Vaginal atrophy most often requires topical (transvaginal) estrogen. Oral and transdermal estrogen supplementation is usually insufficient for Vaginal atrophy as the levels of estrogen achieved in the vaginal tissues is low using those routes. Often transvaginal estrogen is given in addition to oral and transdermal.
Not all patients are good candidates for estrogen supplementation, even using the transvaginal route. Those with a personal or family history of aggressive breast cancer, gynecologic malignancy, blood clots, vascular or cardiac issues should consult their respective specialists.
Response to low dose topical (transvaginal) estrogen may be insufficient to ameliorate the symptoms. Compliance with using the right dose is very important.
FemTouch is a great alternative to topical (transvaginal) estrogen although it too can be used in combination to obtain the desired effect.